Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial

Med

Volumn 1, Issue 1, 2020, Pages 105-113.e4

  Li, Yueping ^a   Xie, Zhiwei ^a   Lin, Weiyin ^a   Cai, Weiping ^a   Wen, Chunyan ^a   Guan, Yujuan ^a   Mo, Xiaoneng ^a   Wang, Jian ^a   Wang, Yaping ^a   Peng, Ping ^a   Chen, Xudan ^a   Hong, Wenxin ^a   Xiao, Guangming ^a   Liu, Jinxin ^a   Zhang, Lieguang ^a   Hu, Fengyu ^a   Li, Feng ^a   Zhang, Fuchun ^a   Deng, Xilong ^a   Li, Linghua ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

arbidol; CAT Scale: Translation to patients; COVID 19; efficacy; lopinavir ritonavir; SARS CoV 2

Indexed keywords

INDOLE DERIVATIVE; LOPINAVIR; RITONAVIR; SULFIDE; UMIFENOVIR;

ADULT; CONTROLLED STUDY; HUMAN; RANDOMIZED CONTROLLED TRIAL;

ADULT; COVID-19 DRUG TREATMENT; HUMANS; INDOLES; LOPINAVIR; RITONAVIR; SARS-COV-2; SULFIDES;

EID: 85105212470     PISSN: 26666359     EISSN: 26666340     Source Type: Journal    
DOI: 10.1016/j.medj.2020.04.001     Document Type: Article

References (20)

1. Wang, Z., Yang, B., Li, Q., Wen, L., Zhang, R., Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin. Infect. Dis., 2020, 10.1093/cid/ciaa272 Published online March 16, 2020.
2. Who Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report –71. 2020 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200331-sitrep-71-covid-19.pdf?sfvrsn=4360e92b_8.
3. Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395 (2020), 565–574.
4. Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8 (2020), 475–481, 10.1016/S2213-2600(20)30079-5.
5. National Health Commission of China. (2020). Diagnosis and treatment of pneumonia caused by new coronavirus (trial version 6). http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml.
6. Mangum, E.M., Graham, K.K., Lopinavir-Ritonavir: a new protease inhibitor. Pharmacotherapy 21 (2001), 1352–1363.
7. Pasquau, J., Hidalgo-Tenorio, C., Montes, M.L., Romero-Palacios, A., Vergas, J., Sanjoaquín, I., Hernández-Quero, J., Aguirrebengoa, K., Orihuela, F., Imaz, A., et al., QoLKAMON STUDY GROUP. High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial. PLoS ONE, 13, 2018, e0195068.
8. Sheahan, T.P., Sims, A.C., Leist, S.R., Schäfer, A., Won, J., Brown, A.J., Montgomery, S.A., Hogg, A., Babusis, D., Clarke, M.O., et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun., 11, 2020, 222.
9. Chan, K.S., Lai, S.T., Chu, C.M., Tsui, E., Tam, C.Y., Wong, M.M., Tse, M.W., Que, T.L., Peiris, J.S., Sung, J., et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med. J. 9 (2003), 399–406.
10. Brooks, M.J., Burtseva, E.I., Ellery, P.J., Marsh, G.A., Lew, A.M., Slepushkin, A.N., Crowe, S.M., Tannock, G.A., Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J. Med. Virol. 84 (2012), 170–181.
11. Popov, A.F., Simakova, A.I., Dmitrenko, K.A., Shchelkanov, M.Y., [Time course of changes in cytokines (IFN-γ, IFN-α, IL-18, TNF-α) in the treatment of moderate influenza A (H1N1) pdm09 (2013-2016) with oseltamivir (Tamiflu) and umifenovir (Arbidol) alone and in combination with Kagocel]. Ter. Arkh. 89 (2017), 66–70.
12. Leneva, I.A., Falynskova, I.N., Makhmudova, N.R., Poromov, A.A., Yatsyshina, S.B., Maleev, V.V., Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study. J. Med. Virol. 91 (2019), 588–597.
13. Khamitov, R.A., Loginova, S.Ia., Shchukina, V.N., Borisevich, S.V., Maksimov, V.A., Shuster, A.M., [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. Vopr. Virusol. 53 (2008), 9–13.
14. Zhang, Q., Wang, Y., Qi, C., Shen, L., Li, J., Clinical trial analysis of 2019-nCoV therapy registered in China. J. Med. Virol., 2020, 10.1002/jmv.25733 Published online February 28, 2020.
15. Jin, Y.H., Cai, L., Cheng, Z.S., Cheng, H., Deng, T., Fan, Y.P., Fang, C., Huang, D., Huang, L.Q., Huang, Q., et al., for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil. Med. Res., 7, 2020, 4.
16. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020, 10.1001/jama.2020.1585 Published online February 7, 2020.
17. Lai, C.C., Shih, T.P., Ko, W.C., Tang, H.J., Hsueh, P.R., Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents, 55, 2020, 105924.
18. Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. 382 (2020), 1787–1799.
19. Chen, J., Ling, Y., Xi, X., Liu, P., Li, F., Li, T., Shang, Z., Wang, M., Shen, Y., Lu, H., Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia. Chin J Epidemiol, 38, 2020, 10.3760/cma.j.cn311365-20200210-00050.
20. Chen, W., Lan, Y., Yuan, X., Deng, X., Li, Y., Cai, X., Li, L., He, R., Tan, Y., Deng, X., et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg. Microbes Infect. 9 (2020), 469–473.